RPTX News and Press, Repare Therapeutics Inc. From 11/15/23

RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARPi, and compelling anti-tumor activity in combination with radio...

2023-11-09 07:50:27 ET More on Repare Therapeutics Repare: Potential Of Camonsertib With Several Shots On Goal Repare Therapeutics: A Compelling Bet On Synthetic Lethality Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for...

Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare to host conference call and webcas...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Repare Therapeutics Inc. (RPTX) is expected to report $-0.86 for Q3 2023

Event to be webcast live on Wednesday, November 15 at 8:00 a.m. ET Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to pre...

2023-11-06 19:43:49 ET Summary Repare Therapeutics presented preliminary results from the phase 1 MYTHIC study using the lunresertib and camonsertib combination for the treatment of patients with multiple solid tumor types. The biotech plans to complete the phase 1 expansion porti...

2023-11-06 12:35:26 ET Moe on Repare Therapeutics Repare Therapeutics: A Compelling Bet On Synthetic Lethality Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therape...

2023-11-06 10:01:49 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...

Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and 50% RECIST response in patients with heavily pre-treated gynecologic tumors, including endome...